Results 11 to 20 of about 4,828 (174)

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. [PDF]

Pediatr Allergy Immunol
Evolution of RSV immunoprophylaxis: from the palivizumab era to next‐generation monoclonal antibodies and future perspectives. Created in BioRender. Abstract The burden of respiratory syncytial virus (RSV) remains a major global health concern in early childhood, responsible for substantial morbidity, hospitalizations, and deaths, particularly in ...
Bizot E, Portet Sulla V, Vauloup-Fellous C, Rameix-Welti MA, Gajdos V, Seddiki N.   +5 more
europepmc   +2 more sources

Palivizumab

Reactions Weekly, 2018
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
  +5 more sources

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants. [PDF]

Clin Pharmacol Ther
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Hu Z, Hellmann F, Zang X, Plock N, Parmar K, Railkar RA, Cheung SYA, Maas BM, Gheyas F.   +8 more
europepmc   +2 more sources

Does Prophylaxis Against Respiratory Syncytial Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?

Journal of Behçet Uz Children's Hospital, 2021
Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun, İbrahim İlker Çetin, Hazım Alper Gürsu   +2 more
doaj   +1 more source

Linking pharmacy dispensing data to other administrative health datasets to measure the compliance and effectiveness of RSV immunoprophylaxis

International Journal of Population Data Science, 2018
Introduction Respiratory Syncytial Virus (RSV) causes considerable morbidity in children. RSV vaccines are in development, but the only current preventive measure is immunoprophylaxis with monoclonal antibody, palivizumab.
Hannah Moore, Tobias Strunk, Tasnim Abdalla, Tom Snelling, Peter Richmond, Anthony Keil, Nicholas de Klerk   +6 more
doaj   +1 more source

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation

Frontiers in Nutrition, 2020
Oral administration of engineered immunoglobulins has the potential to prevent enteric pathogen-induced diarrhea in infants. To prevent infection, these antibodies need to survive functionally intact in the proteolytic environment of the gastrointestinal
Baidya Nath P. Sah, Jiraporn Lueangsakulthai, Bum Jin Kim, Benjamin R. Hauser, Yeonhee Woo, Amy Olyaei, Molly Aloia, Ann O'Connor, Brian Scottoline, Manoj K. Pastey, David C. Dallas   +10 more
doaj   +1 more source

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BMC Pediatrics, 2020
Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV).
Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore   +7 more
doaj   +1 more source

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Drugs in Context, 2015
Background: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect
Saleh al-Alaiyan, Paul Pollack, Gerard F Notario   +2 more
doaj   +1 more source

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study

Italian Journal of Pediatrics, 2023
Background In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study
Chiara Ratti, Anna della Greca, Deborah Bertoncelli, Monica Rubini, Bertrand Tchana   +4 more
doaj   +1 more source

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Emerging Infectious Diseases, 2012
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006–2010.
Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, Guy Boivin   +11 more
doaj   +1 more source